PET/MRI in Breast Cancer

Pujara, Akshat C.; Kim, Eric; Axelrod, Deborah; Melsaether, Amy N.

doi:10.1002/jmri.26298

Cited by 34 publications

(20 citation statements)

References 91 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…investigated the diagnostic performance of 18F-FDG PET/MRI for hepatic metastases in a diverse group of patients with primary malignancy. Similar to the results in this systematic review, they found very good diagnostic accuracy for the detection of hepatic metastases with a patient-level meta-analytic summery sensitivity of 99.2% and specificity of 98.6% [ 11 , 26 , 48 ]. Especially in subcentimeter hepatic metastases, the reported sensitivity of 18F-FDG PET/MRI outperforms that achieved by 18F-FDG PET/CT [ 48 ].…”

Section: Discussionsupporting

confidence: 81%

“…Theoretically, 18F-FDG PET/MRI could offer an attractive one-stop-shop solution for patients with locally advanced breast cancer with affected axillary lymph nodes who should undergo both breast MRI for locoregional staging and whole-body 18F-FDG PET/CT for nodal and distant staging. 18F-FDG PET/MRI could then subsequently be used to assess the response to NST [ 11 , 12 ]. Moreover, using 18F-FDG PET/MRI for breast cancer staging allows the possibility to perform diffusion-weighted imaging (DWI) as part of the MRI protocol.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Diagnostic performance of PET/computed tomography versus PET/MRI and diffusion-weighted imaging in the N- and M-staging of breast cancer patients

Mooij

Amador

Mitea

et al. 2020

Nuclear Medicine Communications

View full text Add to dashboard Cite

show abstract

Section: Discussionsupporting

confidence: 81%

Section: Introductionmentioning

confidence: 99%

Diagnostic performance of PET/computed tomography versus PET/MRI and diffusion-weighted imaging in the N- and M-staging of breast cancer patients

Mooij

Amador

Mitea

et al. 2020

Nuclear Medicine Communications

View full text Add to dashboard Cite

show abstract

“…Dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) is both a morphological and functional imaging tool and is the most sensitive technique to date for breast cancer screening (29). DCE-MRI is frequently used in breast cancer staging and treatment monitoring (30). Integrated PET/MRI, which can acquire both metabolic data and high-contrast morphological images in a single exam, has recently been used more often in breast cancer patients.…”

Section: Pet/mrimentioning

confidence: 99%

“…Although sentinel lymph node (SLN) mapping and biopsy are routinely applied to evaluate lymph-node metastases of breast cancer, imaging techniques are utilized as additional modalities in nodal assessment. Most studies have indicated that PET-based imaging is more sensitive in detecting axillary metastases than MRI (30). Figure 3 shows an example of the imaging lymph-node metastasis in a 66-year-old female patient with right breast cancer by PET/CT and MRI.…”

Section: Imaging the Lymph-node Metastasesmentioning

confidence: 99%

Progress and Future Trends in PET/CT and PET/MRI Molecular Imaging Approaches for Breast Cancer

Ming

Qian

et al. 2020

Front. Oncol.

View full text Add to dashboard Cite

Breast cancer is a major disease with high morbidity and mortality in women worldwide. Increased use of imaging biomarkers has been shown to add more information with clinical utility in the detection and evaluation of breast cancer. To date, numerous studies related to PET-based imaging in breast cancer have been published. Here, we review available studies on the clinical utility of different PET-based molecular imaging methods in breast cancer diagnosis, staging, distant-metastasis detection, therapeutic and prognostic prediction, and evaluation of therapeutic responses. For primary breast cancer, PET/MRI performed similarly to MRI but better than PET/CT. PET/CT and PET/MRI both have higher sensitivity than MRI in the detection of axillary and extra-axillary nodal metastases. For distant metastases, PET/CT has better performance in the detection of lung metastasis, while PET/MRI performs better in the liver and bone. Additionally, PET/CT is superior in terms of monitoring local recurrence. The progress in novel radiotracers and PET radiomics presents opportunities to reclassify tumors by combining their fine anatomical features with molecular characteristics and develop a beneficial pathway from bench to bedside to predict the treatment response and prognosis of breast cancer. However, further investigation is still needed before application of these modalities in clinical practice. In conclusion, PET-based imaging is not suitable for early-stage breast cancer, but it adds value in identifying regional nodal disease and distant metastases as an adjuvant to standard diagnostic imaging. Recent advances in imaging techniques would further widen the comprehensive and convergent applications of PET approaches in the clinical management of breast cancer.

show abstract

“…Synchronized multiparametric 18 F-uoro-2-deoxy-d-glucose ( 18 F-FDG) PET/MRI is a novel imaging technique that combines multiparametric morphologic and functional information from MRI with metabolic information provided by PET offering unique insights into tumor biology to achieve the ultimate goal of precision medicine in oncology [7,8]. Recent data support the use of 18 F-FDG PET/MRI in breast cancer patients for different diagnostic purposes [9,10]. Initial data using the combination of separately acquired MRI and PET data indicate an improvement in the differentiation of benign and malignant breast lesions [11], but at present the role of synchronized multiparametric 18 F-FDG PET/MRI for breast cancer diagnosis has not been fully assessed.…”

Section: Introductionmentioning

confidence: 99%

AI-enhanced Synchronized Multiparametric 18F-FDG PET/MRI for Accurate Breast Cancer Diagnosis

Romeo

Clauser

Rasul

et al. 2021

Preprint

View full text Add to dashboard Cite

Purpose: to assess whether a radiomics and machine learning (ML) model combining quantitative parameters and radiomics features extracted from synchronized multiparametric 18F-FDG PET/MRI images can differentiate benign and malignant breast lesions.Methods: 102 consecutive patients with 120 BI-RADS 0, 4 and 5 breast lesions (101 malignant, 19 benign) detected by ultrasound and/or mammography were prospectively enrolled and underwent hybrid 18F-FDG PET/MRI for diagnostic purposes. Quantitative parameters and radiomics features were extracted from dynamic contrast-enhanced (MTT, VD, PF), diffusion (ADCmean of breast lesions and contralateral breast parenchyma), PET (SUVmax, mean and minimum of breast lesions, SUVmean of uni- and contralateral breast parenchyma) and T2-w images. Different diagnostic models were developed using a fine gaussian support vector machine algorithm and exploring different combinations of quantitative parameters and radiomics features to obtain the highest accuracy in discriminating benign from malignant breast lesions using a 5-fold cross validation. The performance of the best radiomics and ML model was compared with that of expert readers review physician using the McNemar test.Results: Eight radiomics models were developed. The integrated model combining MTT and ADC with radiomics features extracted from PET and ADC images obtained the highest accuracy for breast cancer diagnosis (AUC 0.983) and was higher (AUC 0.868) yet not significant to expert readers review (p=0.508).Conclusion: A radiomics and ML model combining quantitative parameters and radiomics features extracted from synchronized multiparametric 18F-FDG PET/MRI images can accurately discriminate benign from malignant breast lesions.

show abstract

PET/MRI in Breast Cancer

Abstract: View this article online at wileyonlinelibrary.com.

Cited by 34 publications

References 91 publications

Diagnostic performance of PET/computed tomography versus PET/MRI and diffusion-weighted imaging in the N- and M-staging of breast cancer patients

Diagnostic performance of PET/computed tomography versus PET/MRI and diffusion-weighted imaging in the N- and M-staging of breast cancer patients

Progress and Future Trends in PET/CT and PET/MRI Molecular Imaging Approaches for Breast Cancer

AI-enhanced Synchronized Multiparametric 18F-FDG PET/MRI for Accurate Breast Cancer Diagnosis

Contact Info

Product

Resources

About